Leukemia & lymphoma · 2024
Association of the pre-transplant CD4/CD8 ratio with the prognosis following allogeneic hematopoietic stem cell transplantation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nagayama Takashi, Fujiwara Shin-Ichiro, Tominaga Ryutaro, Yokoyama Daizo, Noguchi Atsuto, Furuki Shuka, Oyama Takashi, Koyama Shunsuke, Murahashi Rui, Nakashima Hirotomo, Ikeda Takashi, Hyodo Kazuki, Kawaguchi Shin-Ichiro, Toda Yumiko, Umino Kento, Minakata Daisuke, Morita Kaoru, Ashizawa Masahiro, Yamamoto Chihiro, Hatano Kaoru, Sato Kazuya, Ohmine Ken, Kanda Yoshinobu
Аннотация
The tumor microenvironment's cells can promote or inhibit tumor formation, and there are no reports on the CD4/CD8 ratio's association with outcomes post allogeneic hematopoietic stem cell transplantation (allo-HSCT). We retrospectively evaluated the pre-transplant peripheral blood CD4/CD8 ratio in 168 patients who underwent their first allo-HSCT for hematological malignancies at our institution. When patients were divided into two groups according to the median CD4/CD8 ratio 1.35 (range, 0.09-19.89), the high CD4/CD8 ratio group had a higher incidence of relapse, equivalent non-relapse mortality and worse overall survival (OS) than the low CD4/CD8 ratio group. In a multivariate analysis, the CD4/CD8 ratio was significantly associated with an increased risk of relapse, although there was a marginally significant difference in OS. The pre-transplant peripheral blood CD4/CD8 ratio could be a novel biomarker for predicting the prognosis of allo-HSCT.